미국의 창상 치료 시장 규모는 2023년 52억 1,000만 달러에 달했습니다. 이 시장은 2031년 90억 2,000만 달러에 달할 것으로 예상되며, 2024-2031년의 예측 기간 동안 7.1%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 고령화 인구 증가, 수술 건수 증가, 만성 창상, 궤양 및 당뇨병성 궤양 유병률 증가, 다양한 창상 치료를 위한 첨단 제품 출시에 대한 주요 기업의 초점 전환이 미국 시장을 주도하고 있습니다.
최근 몇 년동안 시장은 혁신적인 창상 드레싱, 생물학적 제제, 재생 의료 접근법 등 창상 치료 기술이 크게 발전해 왔으며, 이는 모두 치유 과정과 환자 결과를 개선하는 것을 목표로 하고 있습니다. 이 시장 특징은 전통적인 창상 드레싱, 음압창상치료, 고압 산소 요법, 생물학적 활성 창상 드레싱 및 대체 피부와 같은 첨단 창상 치료 제품 등 다양한 제품 및 서비스가 있다는 점입니다. 재택의료와 외래 창상 치료 클리닉이 각광을 받으면서 환자들은 기존 병원 외의 장소에서 양질의 창상 치료를 받을 수 있게 되었습니다. 그 결과, 미국의 창상 치료 시장은 만성적인 창상와 부상을 입은 환자들의 전반적인 삶의 질을 향상시키는 데 초점을 맞추는 환자 중심 시장으로 변모하고 있습니다. 제약회사부터 의료기기 제조업체에 이르기까지 시장 관계자들은 이러한 수요 증가에 대응하고 미국 내 창상 치료의 성과를 더욱 향상시키기 위해 연구개발에 투자하고 있습니다.
이 보고서는 미국의 창상 치료 시장에 대해 조사했으며, 시장 개요와 함께 제품별/용도별/구매 형태별/유통 채널별/최종 사용자별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
United States wound care market size was valued at USD 5.21 billion in 2023, and is expected to reach USD 9.02 billion in 2031, with a CAGR of 7.1% for the forecast period between 2024 and 2031F. The growing aging population, increasing number of surgical procedures, increasing prevalence of chronic wounds, ulcers, and diabetic ulcers, and the shift in focus of key players to launch advanced products to treat various wounds are driving the market in the United States.
In recent years, the market has witnessed significant advancements in wound care technologies, including innovative wound dressings, biologics, and regenerative medicine approaches, all aimed at improving the healing process and patient outcomes. The market is characterized by a diverse range of products and services, including traditional wound dressings, negative pressure wound therapy, hyperbaric oxygen therapy, and advanced wound care products such as bioactive wound dressings and skin substitutes. Home healthcare and outpatient wound care clinics have gained prominence, enabling patients to receive high-quality wound care outside traditional hospital settings. As a result, the United States wound care market has become increasingly patient-centric, focusing on improving the overall quality of life for individuals dealing with chronic wounds and injuries. Market players, ranging from pharmaceutical companies to medical device manufacturers, are investing in research and development to meet this growing demand and further enhance wound care outcomes in the United States
The growing presence of established hospitals featuring specialized wound management centers stands out as a pivotal driver for market expansion. Furthermore, the increase in the admission of patients with chronic wounds can be attributed to the presence of advanced medical equipment and the comprehensive reimbursement policies extended by hospitals, further fueling the growth of the United States wound care market. Additionally, hospitals are forging partnerships with key industry players to increase awareness and deliver acute wound management services, thereby fostering market advancement. In April 2022, Healogics collaborated with Vizient Hospital to efficiently deliver outpatient wound management and treatment services. In December 2021, Smith & Nephew obtained FDA approval for its PICO 7 Single Use Negative Pressure Wound Therapy System, designed for the removal of exudates from a range of wound types. The system is compatible for use in both hospital and homecare settings.
The increasing incidence of both acute and chronic wounds stands as a significant factor shaping the market's growth in the years to come. As per a 2021 article published in NCBI, chronic wounds such as diabetic foot ulcers, pressure ulcers, leg ulcers, and others are mostly found in individuals aged 65 years and older, with an expected impact on around 2% of the entire population of the United States. According to a 2022 report released by the Centers for Disease Control and Prevention, approximately 37.3 million individuals in the United States were living with diabetes. Furthermore, numerous research articles have reported that approximately 2-5% of the United States population with diabetes mellitus develop diabetic foot ulcers. As reported by the Agency for Healthcare Research and Quality, approximately 2.5 million individuals in the United States experience pressure ulcers each year. Additionally, these ulcers are notably common among the elderly population. Moreover, according to data from the United Health Foundation, there are approximately 54 million adults aged 65 years and older residing in the country, and this figure is anticipated to grow to 85.7 million by 2050. Consequently, the increasing population of elderly individuals is expected to increase the likelihood of pressure ulcers among this group, consequently driving the demand for chronic wound treatment products in the future.
The market is expected to witness a surge in product adoption among patients, primarily due to the changing priorities of prominent companies like ConvaTec Group Plc and Smith & Nephew, who are placing greater emphasis on research and development, along with the introduction of innovative products in the country. Furthermore, the growing support from regulatory agencies for a wide range of wound management products is projected to further bolster the market's expansion. In January 2023, ConvaTec Group PLC introduced ConvaFoam in the United States. The ConvaFoam dressing line incorporates advanced silicone technology to enhance adhesion, extends wear time to seven days, improves absorbency, includes superabsorbent layers, and enables continuous monitoring. These innovations make the product suitable for a wide range of wound types.
Leading companies in the United States actively engage in strategic acquisitions to bolster their presence and expand their product portfolios. These acquisitions reflect the industry's ongoing commitment to innovation and the delivery of advanced wound care products and services, enhancing their capacity to meet the growing healthcare needs of patients across the United States. In November 2022, InfuSystem Holdings, Inc. entered a collaboration with Sanara MedTech Inc., resulting into the establishment of SI Wound Care, LLC. The partnership primarily aims to create a comprehensive wound management solution aimed at enhancing patient outcomes while effectively reducing costs. In November 2021, Convatec Group PLC renewed its contract partnership with Vizient, Inc. for an additional three years, with the overarching goal of providing top-tier products to assist patients and caregivers in their wound care needs.
The pandemic's emergence resulted in a decline in the market. Wound management was excluded from the list of essential procedures during the pandemic, leading to adverse effects on the market. In the initial stages of the pandemic, the healthcare workforce primarily directed their efforts towards crisis management. Additionally, widespread lockdown measures aimed at mitigating virus spread led to the closure of non-essential clinics and postponed patient visits, significantly affecting the market. According to a 2021 research article published by HMP Global, over 40% of wound treatment clinics experienced temporary closures in 2020. Additionally, hospital-based outpatient departments saw a significant decrease of 60% in patient visits during that time. Several industry participants in the nation reported a substantial decrease in their earnings throughout the pandemic. For example, Smith & Nephew, saw a 5.1% drop in revenue from its advanced wound care business segment in 2020 as compared to 2019. This decline was attributed to a reduction in elective surgeries and restrictions placed on healthcare facility access.
The United States wound care market exhibits a semi-consolidated structure, with a selected group of established players operating in the advanced wound products sector, while others focus on traditional products. Prominent companies like 3M, Smith & Nephew, and Convatec Group PLC, among others, command a substantial share in the United States wound care market. The growth of these companies is driven by a surge in strategic initiatives, including the introduction of new products, the expansion of sales channels, and the adoption of inorganic strategies to fortify their market presence within the country. In January 2023, ConvaTec Group PLC introduced ConvaFoam in the United States. The ConvaFoam dressing line incorporates advanced silicone technology to enhance adhesion, extends wear time to seven days, improves absorbency, include superabsorbent layers, and enable exudate monitoring.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.